Table 5.
The sustained virologic response (SVR) to DAA in patients during 24 weeks of DAA therapy and follow-up.
| Time | Weeks | SVR | Regimen 1 (SOF + DCV) (n = 37) | Regimen 2 (SOF + LDV) (n = 16) | DAA (n = 53) |
|---|---|---|---|---|---|
| DAA therapy | Week 4 | – | 81.1% (30) | 87.5% (14) | 83% (44) |
| Week 8 | – | 91.9% (34) | 93.8% (15) | 92.4% (49) | |
| Week 12 | – | 97.3% (36) | 100% (16) | 98.1% (52) | |
| Follow up | Week 16 | SVR-4 | 94.6% (35) | 93.8% (15) | 94.3% (50) |
| Week 24 | SVR-12 | 94.6% (35) | 93.8% (15) | 94.3% (50) |
SOF, Sofosbuvir; LDV, Ledipasvir; DCV, Daclatasvir; DAA, Direct-Acting Antiviral; SOF, Sofosbuvir, LDV, Ledipasvir, DCV, Daclatasvir, SVR, Sustained virologic response.